BIOMARKER:

CHEK2 mutation

A2 | Sensitive

B | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

A2 | Resistant

B | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

Prostate Cancer

HER2 Negative Breast Cancer

Tongue Carcinoma

Ovarian Cancer

Pancreatic Ductal Adenocarcinoma

Testicular Cancer

Breast Cancer

olaparib

CHEK2 mutation|Prostate Cancer|olaparib

CHEK2 mutation|Ovarian Cancer|olaparib

talazoparib

CHEK2 mutation|HER2 Negative Breast Cancer|talazoparib

CHEK2 mutation|Testicular Cancer|talazoparib

ABT-888 + M6620

CHEK2 mutation|Tongue Carcinoma|ABT-888 + M6620

pembrolizumab

CHEK2 mutation|Prostate Cancer|pembrolizumab

durvalumab

CHEK2 mutation|HER2 Negative Breast Cancer|durvalumab

rucaparib

CHEK2 mutation|Prostate Cancer|rucaparib

irinotecan

CHEK2 mutation|Pancreatic Ductal Adenocarcinoma|irinotecan

CDK4 inhibitor + CDK6 inhibitor

CHEK2 mutation|Breast Cancer|CDK4 inhibitor + CDK6 inhibitor